lrh-1

LRH-1 Inhibitor-3 is the first small molecule LRH-1 activity antagonist.

LRH-1 modulator-1 is a potent modulator agonist of LRH-1 (liver receptor homolog-1). LRH-1 modulator-1 induces the anti-inflammatory cytokine IL-10 and exhibits inhibition of the inflammatory cytokines IL-1b and TNFa. LRH-1 modulator-1 has anti-inflammatory activity in intestinal-like organs.

RJW100 is a compound that acts as a potent agonist of liver receptor homolog 1 (LRH-1, NR5A2) and steroidogenic factor-1 (SF-1, NR5A1), exhibiting pEC50 values of 6.6 and 7.5, respectively. Additionally, RJW100 induces robust activation of the miR-200c (miRNA-200c, microRNA-200c) promoter.

(Iso)-RJW100 is a potent liver receptor homolog 1 (LRH-1, NR5A2) and steroidogenic factor-1 (SF-1, NR5A1) agonist with pEC 50 s of 6.4 and 7.2, respectively.

7-[4-(2-Piperidinyl)ethoxy]benzoyl Raloxifene is an LRH-1 antagonist with an IC50 of 3.1 μM.

ML-180 (SR1848) is a potent inverse agonist of the orphan nuclear receptor liver receptor homolog 1 (LRH-1; NR5A2) with an IC50 of 3.7 μM.

DLPC is an LRH-1 agonist ligand. DLPC is a phospholipid for biological study[1][2].

SS-RJW100 is an enantiomer of RJW100, known as a racemic agonist that targets two nuclear receptors: liver receptor homolog 1 (LRH-1) and steroidogenic factor 1 (SF-1). In vitro experiments reveal that SS-RJW100 promotes the recruitment of coregulator protein fragments and enhances the interaction with the transcriptional intermediary factor 2 (Tif2) coactivator specifically for LRH-1. Additionally, SS-RJW100 disrupts the allosteric activation networks of LRH-1, displaying suboptimal thermal stability [1] [2].

RR-RJW100, an enantiomer of RJW100, functions as an agonist for both nuclear receptor liver receptor homolog 1 (LRH-1) and steroidogenic factor 1 (SF-1). Among its two synthesized enantiomers, RR-RJW100 and SS-RJW100, the former exhibits greater potency as an LRH-1 agonist. This compound plays a crucial role in regulating metabolic homeostasis and is utilized in researching diabetes, liver disease, and inflammatory bowel disease.

TPNQRQNVC, a nonapeptide epitope of HLA-B0702, induces a CD8+ T cell immune response [1].